Ablative Solutions is a medical device company that has developed a best-in-class drug delivery catheter, the Peregrine SystemTM, which delivers a neurolytic agent to the adventitia of the renal arteries for the purposes of ablating the surrounding nerves.
This procedure, known as renal denervation, has a potentially significant effect in the treatment of hypertension.
The Ablative Solutions procedure is quick, relatively painless and results in deep, circumferential ablation of the renal nerves.
The company has CE Mark and is currently engaged in clinical studies in Europe and the United States.
This procedure, known as renal denervation, has a potentially significant effect in the treatment of hypertension.
The Ablative Solutions procedure is quick, relatively painless and results in deep, circumferential ablation of the renal nerves.
The company has CE Mark and is currently engaged in clinical studies in Europe and the United States.
Location: United States, California, San Jose
Employees: 11-50
Total raised: $99.8M
Founded date: 2011
Investors 3
Funding Rounds 4
| Date | Series | Amount | Investors |
| 03.01.2019 | Series D | $77M | Gilde Heal... |
| 04.02.2014 | Series B | $9.5M | - |
| 08.11.2013 | - | $8M | - |
| 19.06.2012 | Series A | $5.3M | - |
Mentions in press and media 13
| Date | Title | Description |
| 03.01.2019 | Ablative Solutions Nabs $77M Series D | KALAMAZOO, MI, Ablative Solutions, a company pioneering new approaches for the treatment of hypertension, today announced the first close of its $77 million Series D funding round. >> Click here for more funding data on Ablative So... |
| 03.01.2019 | Ablative Solutions Raises $77M Financing Round | Ablative Solutions, Inc., a Kalamazoo, MI-based company advancing innovative solutions for the treatment of hypertension, held the first close of its $77m Series D funding round. The round was led by new investor Gilde Healthcare and co-led... |
| 03.01.2019 | Michigan medtech company raises $77M for renal denervation solution to hypertension | While the development of renal denervation technologies stalled after a failed Medtronic study in 2014, recent positive research results have led to increasing interest – and investment – in the space. Case in point, Kalamazoo, Michigan-bas... |
| 03.01.2019 | Gilde Healthcare leads USD 77 million financing round of hypertension company Ablative Solutions | Utrecht (The Netherlands), Boston (United States) – Ablative Solutions, Inc. (Kalamazoo, Michigan), a medtech company pioneering new approaches for the treatment of hypertension, today announced the first close of its USD 77 million Series ... |
| 20.10.2014 | Ablative Solutions tests infusion ablation catheter as hypertension treatment | Ablative Solutions initiated a study in Poland to test an infusion catheter it believes can treat hypertension by interrupting signals from sympathetic nerves located in the outer layer of the renal artery. The sympathetic nervous system go... |
| 04.02.2014 | Ablative Solutions Completes $9.5M Series B Financing | Ablative Solutions, Inc., a Kalamazoo, MI-based clinical stage company, completed an approximately $9.5m Series B financing. The round was led by BioStar Ventures and Michigan Accelerator Fund, with participation from founders and angel inv... |
| 08.11.2013 | Hypertension: Ablative Solutions lands $8M for renal denervation tech | Ablative Solutions, which is developing perivascular renal denervation technology for treating high blood pressure, raised an $8.0 million funding round, according to a regulatory filing. Menlo Park, Calif.-based Ablative Solutions said 98 ... |
| 15.08.2013 | Hypertension: Ablative Solutions reels in $2.7M for renal denervation device | Ablative Solutions added to its coffers yesterday, reporting a $2.7 million raise out of a hoped-for $5 million as it works to develop its perivascular renal denervation technology for treating high blood pressure. Menlo Park, Calif.-based ... |
| 11.04.2013 | Medtech funding: Ablative Solutions raises $1.1 million | Ablative Solutions reported raising $1.1 million in an April 4, 2013, regulatory filing: Company: Ablative Solutions Raise: $1.1 million Security: Debt, Options/Warrants Investors: 13 Sales Commission: $0 Finders’ Fees: $0 |
| 19.06.2012 | Ablative Solutions Completes $5.3M Series A Financing | Ablative Solutions, Inc., a Kalamazoo, MI-based company that develops and markets proprietary, endovascular catheters to provide an alternative to surgical renal denervation for the treatment of hypertension, has completed a $5.3m Series A ... |
Show more